These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28326839)

  • 21. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
    Jamison JK; Zhou M; Gelmann EP; Luk L; Bates SE; Califano A; Fojo T
    Oncologist; 2024 Sep; 29(9):817-e1213. PubMed ID: 38886159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
    Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
    Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
    Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
    Yeruva SLH; Zhao F; Miller KD; Tevaarwerk AJ; Wagner LI; Gray RJ; Sparano JA; Connolly RM
    NPJ Breast Cancer; 2018; 4():1. PubMed ID: 29354686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer epigenetics: current and evolving treatment.
    Purja S; Nguyen DT; Kim E
    Breast Cancer; 2024 Sep; 31(5):869-885. PubMed ID: 38861041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
    Iwata H; Nakamura R; Masuda N; Yamashita T; Yamamoto Y; Kobayashi K; Tsurutani J; Iwasa T; Yonemori K; Tamura K; Aruga T; Tokunaga E; Kaneko K; Lee MJ; Yuno A; Kawabata A; Seike T; Kaneda A; Nishimura Y; Trepel JB; Saji S
    Jpn J Clin Oncol; 2023 Jan; 53(1):4-15. PubMed ID: 36398439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
    Azad NS; El-Khoueiry A; Yin J; Oberg AL; Flynn P; Adkins D; Sharma A; Weisenberger DJ; Brown T; Medvari P; Jones PA; Easwaran H; Kamel I; Bahary N; Kim G; Picus J; Pitot HC; Erlichman C; Donehower R; Shen H; Laird PW; Piekarz R; Baylin S; Ahuja N
    Oncotarget; 2017 May; 8(21):35326-35338. PubMed ID: 28186961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
    Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
    Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
    Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
    Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.
    von Tresckow B; Sayehli C; Aulitzky WE; Goebeler ME; Schwab M; Braz E; Krauss B; Krauss R; Hermann F; Bartz R; Engert A
    Eur J Haematol; 2019 Feb; 102(2):163-173. PubMed ID: 30347469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
    Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
    Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
    Schech A; Kazi A; Yu S; Shah P; Sabnis G
    Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner.
    Li H; Xu X; Zhang Y; Tang X; Li W
    Eur J Pharmacol; 2020 Dec; 888():173575. PubMed ID: 32950498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
    Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
    Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
    Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
    J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.